Last reviewed · How we verify
FEC→T
FEC→T is a sequential chemotherapy regimen combining fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel to kill rapidly dividing cancer cells.
FEC→T is a sequential chemotherapy regimen combining fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel to kill rapidly dividing cancer cells. Used for Breast cancer (neoadjuvant or adjuvant treatment).
At a glance
| Generic name | FEC→T |
|---|---|
| Also known as | Epirubicin, Cyclophosphamide, Fluorouracil, Taxotere |
| Sponsor | Karolinska University Hospital |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FEC (5-fluorouracil, epirubicin, cyclophosphamide) is a combination chemotherapy that damages DNA and inhibits cell division through multiple mechanisms. The subsequent taxane (docetaxel) stabilizes microtubules and prevents mitotic spindle formation. This sequential approach leverages different cytotoxic mechanisms to maximize tumor cell death in breast cancer.
Approved indications
- Breast cancer (neoadjuvant or adjuvant treatment)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Mucositis
- Cardiotoxicity
- Peripheral neuropathy
Key clinical trials
- Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients (PHASE3)
- Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (PHASE3)
- PET/MRI in Patients With Suspected Prostate Cancer (PHASE3)
- Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer (PHASE2)
- BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (PHASE3)
- Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) (PHASE3)
- MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (PHASE4)
- Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FEC→T CI brief — competitive landscape report
- FEC→T updates RSS · CI watch RSS
- Karolinska University Hospital portfolio CI